Project Grant R43HL184590
Award Date 8/1/26
Completion Date 7/31/27
Dollars Obligated $314K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Athens, GA 30602, USA
Similar Awards
- The National Heart Lung and Blood Institute awarded Nusirt Sciences, Inc. $2,095,691 on September 15, 2025, to conduct clinical validation of NS-0200, a fixed combination drug product for the treatment of hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). Work is performed in West Virginia. The period of performance runs through June 30, 2027. The award is structured as a Project Grant, an assistance type commonly used for small business innovation research in the...
- The National Institute of General Medical Sciences, part of the Department of Health and Human Services National Institutes of Health, awarded Nanos, Inc. $613,456 on September 11, 2025, under the Biomedical Research and Research Training program (CFDA 93.859) to develop and test a topical nitrite ointment that reverses nitroglycerin tolerance. Nanos, Inc. will formulate a water-in-oil ointment for topical nitrite application designed to enable slow uptake into circulation and prolong...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Nimble Surgical Incorporated $314,362 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop FLEXLOCK, a manually operable anchoring guide catheter designed to simplify transradial complex percutaneous coronary interventions. FLEXLOCK delivers simultaneous active and passive support through an anchoring tip to provide stable coronary access during complex PCI...
- The National Heart Lung and Blood Institute awarded Inomagen Therapeutics, Inc. $1,412,149 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance IGN001, a non-viral short hairpin RNA plasmid designed to silence NOX2 and modify the disease substrate in atrial fibrillation without destroying atrial tissue. The recipient will conduct three aims: define the dose-dependent molecular activity and safety of IGN001 in healthy canines by assessing NOX2...
- The National Heart, Lung, and Blood Institute awarded Tiba Biotech LLC $396,805 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 1, 2026, for development of lung-targeting delivery systems for small interfering RNA therapeutics. Tiba Biotech is advancing a proprietary non-viral RNA delivery platform called RNABL, which employs dendritic aminoalkyl-branched lipidoids as nanoparticle carriers. The platform addresses a critical gap in nucleic acid therapeutics: achieving...
- The National Heart, Lung, and Blood Institute awarded Cmtx Biotech Inc. $367,988 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a lung-specific, sulfonium lipid nanoparticle formulation of Incyclinide (CMT-3/SLNP) for treating acute respiratory distress syndrome in sepsis patients. This Phase I Small Business Technology Transfer project will evaluate the formulation and delivery of CMT-3/SLNP, a chemically modified, non-antibiotic tetracycline...
- The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...
- The National Heart, Lung, and Blood Institute awarded Minnesota Healthsolutions Corporation $329,537 on August 15, 2026, to develop a novel balloon angioplasty inflation device under the Cardiovascular Diseases Research program (CFDA 93.837). The recipient will design and evaluate a prototype inflation device intended to improve safety and efficacy during percutaneous balloon angioplasty by accounting for molecular composition and elasticity differences in arterial tissue. Current market devices...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded Anova Biomedical, Inc. $345,938 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop compliant and degradable peripheral vascular grafts for small-artery bypass procedures. Anova is refining fabrication techniques for NovaGraft, a vascular bypass graft made from a novel, fully degradable elastomer designed to match the mechanical properties of native arteries. The work...
- The National Heart, Lung, and Blood Institute awarded Medluidics LLC $227,639 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a cardiopulmonary unit-on-a-chip for investigating right ventricular hypertrophy caused by pulmonary arterial hypertension and for developing targeted treatments. The recipient will develop a microfluidic device that models both the right ventricle and pulmonary artery separated by a collagen layer, enabling culture of...